This yields a neuropathology-validated pseudo-continuous APOE risk score that was previously shown to be more sensitive to predict AD progression compared to alternative forms of APOE scores, such as the binary classification into APOE ε4 carriers vs non-carriers [50]. The gene discussed is APOE; the disease is Alzheimer disease.